Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)
34.27
-1.48 (-4.14%)
Nov 17, 2026, 4:00 PM EST
SHE:301281 Revenue
Shandong Keyuan Pharmaceutical had revenue of 151.07M CNY in the quarter ending September 30, 2026, with 101.90% growth. This brings the company's total for the last twelve months to 578.07M, up 32.73% year-over-year. In the year 2025, Shandong Keyuan Pharmaceutical had annual revenue of 398.23M, down -14.12%. That makes Shandong Keyuan Pharmaceutical the 23,827th largest company in the world by revenue and 4,290th in China.
Revenue (ttm)
578.07M
Revenue Growth
+32.73%
P/S Ratio
6.42
Revenue / Employee
889.34K
Employees
650
Market Cap
3.71B
Revenue by Geography
- East China 194.30M 48.8%
- North China 82.65M 20.8%
- Overseas 43.71M 11.0%
- Southwest 34.22M 8.6%
- Central China 17.92M 4.5%
- Northeast 11.90M 3.0%
- South China 10.15M 2.5%
- Northwest 3.38M 0.8%
Fiscal year ended Dec 31, 2025 See the full SHE:301281 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 398.23M | -65.49M | -14.12% |
| Dec 31, 2024 | 463.72M | 16.13M | 3.60% |
| Dec 31, 2023 | 447.58M | 4.72M | 1.07% |
| Jan 1, 2023 | 442.87M | 21.98M | 5.22% |
| Jan 1, 2022 | 420.89M | 53.83M | 14.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 55.52B |
| Zhejiang Int'l Group | 34.69B |
| Shanghai Shenqi Pharmaceutical Investment Management | 1.80B |
| Zhejiang Zhenyuan Share | 1.79B |
| GuangYuYuan Chinese Herbal Medicine | 1.31B |
| Hangzhou Minsheng Healthcare | 902.62M |
| Hubei Guangji Pharmaceutical | 630.16M |
| Hangzhou Bio-Sincerity Pharma-Tech | 617.95M |